Pittsburgh

US offers investment to boost global COVID-19 vaccine capacity – Pittsburgh, Pennsylvania

Pittsburgh, Pennsylvania 2021-11-17 17:52:00 –

Forced to address the gapped inequality of the global COVID-19 vaccine, the Byden administration has spent billions of dollars to prepare pharmaceutical companies for expanding domestic production and sharing it with the world for the next pandemic. We have taken steps to make it available. The Biomedical Advanced Research and Development Authority is asking pharmaceutical companies that have proven capable of producing more effective mRNA vaccines to bid on US investment in scale-up of production. Pfizer and Modana make two US-approved mRNA shots. The White House hopes this move will build the ability to create an additional billion shots annually. This initiative is a global vaccine supply by the Biden White House — while the United States moves towards approval of booster shots for all adults and vulnerable people in poor countries wait for their first vaccination. According to an analysis of the ONE campaign, an international aid and advocacy group, people living in low-income countries receive their first vaccination. Wealthy countries received more than 173 million booster shots, and low-income countries received about 32 million first shots. Income countries stop preventable death and limit the development of potentially newer, more dangerous variants of the virus. The goal of this program is to start production by the second half of 2022 and add existing capacity 1 billion times a year. “The White House COVID-19 coordinator Jeff Zyentz announced on Wednesday that the United States has donated 250 million COVID-19 vaccines worldwide with the goal of sharing more than 1.1 billion shots. Although there is no firm agreement with Modena or Pfizer to acquire the United States for investment at the end of 2022, the Byden administration hopes to increase its manufacturing capacity with its facilities, equipment, staff, or. Strong support for training will enable more COVID-19 doses to be shared abroad by mid-2022, preparing for the next public health emergency, to stimulate the immune system. The Pfizer and Modana vaccines have proven to be more effective in preventing serious illness and death from COVID-19 than the Johnson & Johnson virus vector vaccine, which uses a harmless virus that carries genetic material to. Made with a genetic code called Messenger RNA, it is trained to recognize the virus to instruct the body to make a harmless copy of the spike protein. Robbie Silverman, Senior Advocacy Manager at Oxfam America. Welcomed Weiden’s plan to invest in vaccine production capacity, but said it was not sufficient. “What the world really needs is the diversification of regional production capacity for vaccines, and this investment. Seems to be focused on building capacity in the United States, “he said. “We need the technology to be transferred by the company that monopolizes the COVID vaccine, and the US government needs to harness that power.” Silberman said, “The company needs to know how to make the COVID-19 vaccine.” If not relocated, Mr. Silberman points out that billions of vaccines against other diseases are routinely made in developing countries and would begin administration to manufacturers elsewhere. Double the time required. It was never too late to act. He said the United States should uphold the proposed exemption drafted by India and South Africa at the World Trade Organization and called for the suspension of patents on COVID-19 vaccines and treatments. “The U.S. government has a lot of free tools to drive pharmaceutical companies,” he said, adding that the U.S. could impose a Defense Production Act targeting key ingredients in COVID-19 shots. He said he had invested billions of dollars. Create a Moderna COVID-19 vaccine. “The United States needs to make sure that these funded companies prioritize public health over profits,” said Ava Alkon, Senior Policy Research Director for Doctors Without Borders, on a US investment. Described the billion doses that could be produced. It’s still far from the numbers needed to immunize the world. The World Health Organization estimates that 11 billion doses are required. Archon said the new drafter of COVID-19 could not be supplied for months, so a quicker solution is needed. “We believe the United States can deliver far more doses than we do on an ongoing basis,” she said, calling for more transparency about how many additional doses the United States has. .. Mr Modana said in a statement that he has not yet considered the Biden administration’s proposal, but is looking forward to discussing it with the government. “And understand if there is a role we can play in supporting the government’s efforts to prepare for a pandemic,” Pfizer declined to comment. The New York Times first reported on a new initiative. Contributed by Maria Chen of London and Laurent Neilgard of Washington, authors of ___AP.

Forced to address the gapped inequality of the global COVID-19 vaccine, the Byden administration didzens on Wednesday to prepare pharmaceutical companies for expanding domestic production and sharing it with the world to prepare for the next pandemic. We have taken steps to make $ 100 million available.

Under the new initiative, the Government’s Biomedical Advanced Research and Development Agency Solicitation of pharmaceutical companies It has a proven ability to produce more effective mRNA vaccines to bid on US investment in manufacturing scale-up. Pfizer and Moderna make two US-approved mRNA shots.

The White House hopes this move will build the capacity to produce an additional billion shots annually.

This initiative begins with the Biden White House facing increasing pressure at home and abroad over global vaccine supply inequality. The United States is moving towards approval of booster shots for all adults, and vulnerable people in poor countries are waiting for their first vaccination.

According to an analysis by the international aid and advocacy organization ONE Campaign, only 4.7% of people living in low-income countries receive initial doses. Wealthy countries received more than 173 million booster shots, and low-income countries received about 32 million first shots.

The Biden administration has increased the capacity of COVID-19 shots to mitigate global dose shortages, especially in low- and middle-income countries, prevent preventable deaths, and potentially newer, more dangerous mutations in the virus. I think it limits the development of the body.

“The goal of this program is to expand our existing capacity by an additional 1 billion times a year and start production by the second half of 2022,” said Jeff Seienz, COVID-19 Coordinator at the White House. I am.

On Wednesday, Zients announced that the United States had donated 250 million COVID-19 vaccines worldwide with the goal of sharing more than 1.1 billion shots by the end of 2022.

There is still no firm agreement with Moderna or Pfizer to buy the United States for investment, but the Biden administration will do more by mid-2022 by strengthening its manufacturing capacity through the support of the company’s facilities, equipment, staff, or training. I hope it will be possible. The dose of COVID-19 will be shared abroad to help prepare for the next public health emergency.

Government proves to be more effective in preventing serious illness and death from COVID-19 than the Johnson & Johnson viral vector vaccine, which uses a harmless virus that carries genetic material to stimulate the immune system. Priority is given to the mRNA vaccine that has been used. Pfizer and Modana vaccines are made with a genetic code called messenger RNA. This code is trained to recognize the virus because it tells the body to make a harmless copy of the spike protein.

Robbie Silverman, senior advocacy manager at Oxfam America, welcomed Biden’s plans to invest in vaccine production capabilities, but said that wasn’t enough.

“What the world really needs is the diversification of regional vaccine production capacity, and this investment seems to be focused on capacity building in the United States,” he said. “We are in desperate need of a company that monopolizes the COVID vaccine to transfer technology, and the US government needs to use that leverage.”

Silberman estimates that if a company does not transfer knowledge about how to make a COVID-19 vaccine, it will take twice as long as manufacturers elsewhere to start administration, what to do with other illnesses. He pointed out that billions of vaccines are routinely manufactured in developing countries.

Silberman said more provisions on vaccine equity should have been negotiated when the United States secured its own supply, but it was never too late to act. He said the United States should uphold the proposed exemption drafted by India and South Africa at the World Trade Organization and called for the suspension of patents on COVID-19 vaccines and treatments. He said the United States could implement the Defense Production Act to target key components of COVID-19 shots.

“The US government has many tools at its disposal to boost pharmaceutical companies,” he said, saying he had invested billions of dollars in the creation of Moderna’s COVID-19 vaccine. “The United States needs to make sure that these funded companies prioritize public health over profit.”

Ava Alkon, senior policy and research director for Doctors Without Borders, said the billion doses that could be produced by US investment are still far from the numbers needed to immunize the world. The World Health Organization estimates that 11 billion doses will be required.

Archon said the new drafter of COVID-19 administration would not be able to supply it for several months and would need a quicker solution. “We believe the United States can deliver far more doses than we do on an ongoing basis,” she said, calling for more transparency about how many additional doses the United States has. .. She said some estimates suggest that the United States could have at least 500 million surplus vaccines by the end of the year.

In his statement, Mr Modana has not yet considered the Biden administration’s proposal, but talks with the government and understands whether we can play a role in supporting the government’s efforts to tackle pandemics. He said he was looking forward to doing it. “” Pfizer declined to comment.

The New York Times first reported on the new initiative.

___

Contributed by Maria Cheng, an AP writer in London, and Lauran Neergaard, Washington.

US offers investment to boost global COVID-19 vaccine capacity Source link US offers investment to boost global COVID-19 vaccine capacity

Back to top button